Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
| Revenue (Most Recent Fiscal Year) | $398.99M |
| Net Income (Most Recent Fiscal Year) | $-257.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.06 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -46.83% |
| Net Margin (Trailing 12 Months) | -46.83% |
| Return on Equity (Trailing 12 Months) | -25.83% |
| Return on Assets (Trailing 12 Months) | -17.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.68 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.08 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.68 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 111.96M |
| Free Float | 106.41M |
| Market Capitalization | $2.23B |
| Average Volume (Last 20 Days) | 0.80M |
| Beta (Past 60 Months) | 0.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.96% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |